Pharmainstru Elec Private Limited - Due diligence report

A 360° intelligence report on Pharmainstru Elec Private Limited: trust score, financial health, credit view, compliance, directors, growth a…

2013-08-08 Thane, Maharashtra Active Unlisted Active Compliant
Share
PE Pharmainstru Elec Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Pharmainstru Elec Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
77/100
Trust Score
Low Risk

Pharmainstru Elec Private Limited is assessed as Low Risk with a Trust Score of 77/100. Pharmainstru Elec Private Limited is an active private limited indian non-government company incorporated in 2013, operating in the Energy and Power sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Pharmainstru Elec Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
65/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 75/100 Low Risk
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2019 - filings overdue.
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
DHANASHRI ASHISH KOLTE 01234567 Director 01/04/2018 6 yrs Approved
ASHISH ARVIND KOLTE 01234567 Director 01/04/2018 6 yrs Approved
DEVENDRA DHANARAJ KOLTE 01234567 Director 01/04/2018 6 yrs Approved
RUPALI DEVENDRA KOLTE 01234567 Director 01/04/2018 6 yrs Approved
PANKAJ ARVIND KOLTE 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2019 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 90 · Distress 65
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
Operating for 12+ years.
Active EPFO - real payroll on record.
Distress signals & risk flags
Revenue declined year-on-year.
Statutory filings appear overdue.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence73/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment63/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view78/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 8 events
30 Sep 2019
Last AGM held
Annual general meeting
31 Mar 2019
Latest balance sheet
Filed with ROC
08 Aug 2013
Incorporated
Registered with Roc Mumbai
Director appointed
DHANASHRI ASHISH KOLTE (Director)
Director appointed
ASHISH ARVIND KOLTE (Director)
Director appointed
DEVENDRA DHANARAJ KOLTE (Director)
Director appointed
RUPALI DEVENDRA KOLTE (Director)
Director appointed
PANKAJ ARVIND KOLTE (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2019 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Vitalticks U33113KA2017PTC104746 Bangalore, Karnataka, India
Manovikas Healthcare Services Private Limited U74999TG2016PTC112793 Hyderavad, Telangana, India
Surya Clinics Private Limited U85110KL2014PTC037030 Thrissur, Kerala, India
Maharaj Vinayak Medical Sciences Private Limited U85110RJ2007PTC024177 Jaipur, Rajasthan, India
Pan Bioscience Private Limited U93000TN2010PTC075826 Chennai, Tamil Nadu, India
Chanda Ayurvedic Pharmacy Private Limited U24232BR2014PTC022413 Jehanabad, Bihar, India
Naik Nursing Home And Endoscopy Centre Private Limited U85100MH2010PTC200647 Thane, Maharashtra, India
Medaxis Healthcare Private Limited U74999DL2016PTC307142 New Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Pharmainstru Elec Private Limited before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Pharmainstru Elec Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Pharmainstru Elec Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Pharmainstru Elec Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Pharmainstru Elec Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Pharmainstru Elec Private Limited an active company?

Pharmainstru Elec Private Limited has MCA status “Active” with a compliance score of 75/100 (Low Risk).

Is Pharmainstru Elec Private Limited financially healthy?

Pharmainstru Elec Private Limited has a Financial Health Score of 65/100 (Moderate) based on its filed financial statements.

Should I do business with Pharmainstru Elec Private Limited?

Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Pharmainstru Elec Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 5 active director(s) are on record.

Does Pharmainstru Elec Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Pharmainstru Elec Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2019 - filings overdue. Overall compliance score: 75/100 (Low Risk).

Is it risky to lend to Pharmainstru Elec Private Limited?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.